| Autor: |
Shoko Yamamoto, Hidekazu Kaneko, Yo Matsumoto, Tohru Suzuki, Noriaki Numata, Kisaburo Deguchi, Masakazu Namihira, Koji Hyodo, Yasuo Sakai |
| Předmět: |
|
| Zdroj: |
Pharmacometrics / Ōyō Yakuri (0300-8533); May2023, Vol. 104 Issue 3/4, p41-54, 14p |
| Abstrakt: |
Cyclo-glycylproline (cGP) promotes neurotrophic effects in damaged brains by regulating the bioavailability of insulin-like growth factor-1(IGF-1). However, further studies regarding the ejects of cGP on the intact brain are necessary to establish it as a fimctional food for normal and healthy brains. In this stud% we investigated the efiect of cGP consumption on cognitive functions in healthy htiman& Furthermore, cGP permeability in intact brains and its effects on monoamine release were investigated by conducting cells culture and microdialysis studies in healthy rats. The findings of this open trial of 10 healthy participants revealed that the administration of 150 mg of cGP for 8 weeks improved cognitive function, particularly in terms of attention and language scores. No adverse events related to cGP administration were observed and our results indicate that cGP used at the dose in this study can improve cognitive functions in healthy humans without adverse effects. Good cGP permeability was observed through the blood-brain barrier in the intact cell culture model, and peroral cGP administration increased cGP concentration in the dialysate from the rats5 striatum. Regarding monoamine release, cGP-fed cells in the intact PC12 cell culture exhibited stimulated releases of dopamine, and cGP-administered healthy rats revealed dopamine metabolite (homovanillic acid) upregulation in the striatum. Therefore, cGP is a promising dietary supplement associated with improved cognitive fiinction in healthy humans. Further investigations are required to bridge the gap between cGP intake and dopamine release. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
